EGFR and cancer: Although it is now given as first-line therapy for EGFR mutant NSCLC [5], patients inevitably develop resistance through single amino acid substitutions at the EGFR cysteine residue C797 as well as other mechanisms that bypass dependence of the cancer cells on EGFR signaling for survival [6].